Suggested remit: To appraise the clinical and cost effectiveness of crovalimab within its marketing authorisation for treating paroxysmal nocturnal haemoglobinuria.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process Cost Comparison Standard
ID number 6140

Provisional Schedule

Expected publication 30 October 2024

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd

Stakeholders

Companies sponsors Roche (crovalimab)
Others Department of Health and Social Care
  NHS England
Patient carer groups None
Professional groups National PNH Service
  Royal College of Physicians
Associated public health groups None
Comparator companies Alexion Pharmaceuticals (eculizumab, ravulizumab) (confidentiality agreement signed, participating)
  Novartis (iptacopan) (confidentiality agreement signed, participating)
  Amgen (eculizumab) (confidentiality agreement not signed, not participating)
  Samsung Bioepis (eculizumab) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
09 April 2024 Invitation to participate
13 September 2023 - 11 October 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6140
13 October 2022 In progress. DHSC referral received
15 June 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual